James Kihara - 07 Apr 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Principal Accounting Officer
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
07 Apr 2022
Net transactions value
-$27,726
Form type
4
Filing time
11 Apr 2022, 20:02:21 UTC
Previous filing
07 Apr 2022
Next filing
27 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +2,977 +619% 3,458 07 Apr 2022 Direct F1
transaction ACAD Common Stock Sale $27,726 -1,025 -30% $27.05 2,433 08 Apr 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -2,977 -50% $0.000000 2,978 07 Apr 2022 Common Stock 2,977 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
F2 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.